|
KMID : 0545120070170111856
|
|
Journal of Microbiology and Biotechnology
2007 Volume.17 No. 11 p.1856 ~ p.1861
|
|
|
Mithramycin Inhibits Etoposide Resistance in Glucose-deprived HT-29 Human Colon Carcinoma Cells
|
|
Lee Eun-Mi
Hwang Ji-Hwan
Park Hae-Ryong
Park Dong-Jin
Chang Kyu-Seob
Kim Chang-Jin
|
|
|
Abstract
|
|
|
|
Physiological cell conditions such as glucose deprivation and hypoxia play roles in the development of drug resistance in solid tumors. These tumor-specific conditions cause decreased expression of DNA topoisomerase IIα, rendering cells resistant to topo II target drugs such as etoposide. Thus, targeting tumor-specific conditions such as a low glucose environment may be a novel strategy in the development of anticancer drugs. On this basis, we established a novel screening program for anticancer agents with preferential cytotoxic activity in cancer cells under glucosedeprived conditions. We recently isolated an active compound, AA-98, from Streptomyces sp. AA030098 that can prevent stress-induced etoposide resistance in vitro. Furthermore, LCMS and various NMR spectroscopic methods identified AA- 98 as mithramycin, which belongs to the aureolic acid group of antitumor compounds. We found that mithramycin prevents the etoposide resistance that is induced by glucose deprivation. The etoposide-chemosensitive action of mithramycin was just dependent on strict low glucose conditions, and resulted in the selective cell death of etoposide-resistant HT-29 human colon cancer cells.
|
|
|
KEYWORD
|
|
|
Glucose deprivation, solid tumor, anticancer, etoposide resistance, mithramycin
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|